|
DK1519714T3
(da)
|
2002-06-28 |
2011-01-31 |
Protiva Biotherapeutics Inc |
Fremgangsmåde og apparat til fremstilling af liposomer
|
|
US20050064595A1
(en)
*
|
2003-07-16 |
2005-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
US9006191B2
(en)
*
|
2007-12-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering RNA
|
|
CA2721333C
(en)
*
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
PL2350043T3
(pl)
|
2008-10-09 |
2014-09-30 |
Tekmira Pharmaceuticals Corp |
Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
|
|
WO2010054406A1
(en)
|
2008-11-10 |
2010-05-14 |
Alnylam Pharmaceuticals, Inc. |
Novel lipids and compositions for the delivery of therapeutics
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
CA2767129C
(en)
*
|
2009-07-01 |
2015-01-06 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
NZ600725A
(en)
*
|
2009-12-18 |
2015-08-28 |
Univ British Colombia |
Methods and compositions for delivery of nucleic acids
|
|
US20130129811A1
(en)
*
|
2010-04-28 |
2013-05-23 |
Takeshi Kuboyama |
Cationic lipid
|
|
WO2011136368A1
(ja)
|
2010-04-28 |
2011-11-03 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
HUE026646T2
(en)
|
2010-07-06 |
2016-07-28 |
Glaxosmithkline Biologicals Sa |
Preferred liposomes containing lipids of PKA value for delivery of RNA
|
|
HRP20161352T1
(hr)
|
2010-07-06 |
2016-12-02 |
Glaxosmithkline Biologicals Sa |
Čestice nalik na virione za unos samoreplicirajućih molekula rna
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
ES2586580T3
(es)
|
2010-07-06 |
2016-10-17 |
Glaxosmithkline Biologicals Sa |
Inmunización de mamíferos grandes con dosis bajas de ARN
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK4226941T3
(da)
|
2010-08-31 |
2024-12-02 |
Glaxosmithkline Biologicals Sa |
Pegylerede liposomer til levering af immunogen-kodende rna
|
|
CA2821992A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR102266691B1
(ko)
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
WO2012162210A1
(en)
*
|
2011-05-26 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
Ring constrained cationic lipids for oligonucleotide delivery
|
|
US11896636B2
(en)
|
2011-07-06 |
2024-02-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
HRP20220250T1
(hr)
|
2011-10-03 |
2022-04-29 |
Modernatx, Inc. |
Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
|
|
HK1200089A1
(en)
|
2011-12-07 |
2015-07-31 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
SI2791160T1
(sl)
|
2011-12-16 |
2022-07-29 |
Modernatx, Inc. |
Sestave modificirane MRNA
|
|
CN104125826A
(zh)
*
|
2011-12-22 |
2014-10-29 |
努沃研究有限责任公司 |
亚氯酸盐或氯酸盐脂质体组合物
|
|
US9035039B2
(en)
*
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
PT2817287T
(pt)
|
2012-02-24 |
2018-12-28 |
Arbutus Biopharma Corp |
Lípidos catiónicos trialquílicos e seus métodos de utilização
|
|
DK2830595T3
(da)
|
2012-03-29 |
2019-12-02 |
Translate Bio Inc |
Ioniserbare kationiske lipider
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
HK1206612A1
(en)
*
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
|
AU2013243952A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
EP2841108A4
(en)
|
2012-04-25 |
2015-11-25 |
Tufts College |
SILK MICRO BEADS AND METHOD OF SURFACE LUBRICATION
|
|
SMT202200337T1
(it)
|
2012-11-26 |
2022-09-14 |
Modernatx Inc |
Rna modificato al livello del terminale
|
|
BR112015013784A2
(pt)
|
2012-12-12 |
2017-07-11 |
Massachusetts Inst Technology |
aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
|
|
US20160002628A1
(en)
*
|
2013-03-11 |
2016-01-07 |
Georgia Tech Research Corporation |
Methods and compositions for managing vascular conditions
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CN105683379A
(zh)
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
DK3011031T3
(da)
|
2013-06-17 |
2020-12-21 |
Broad Inst Inc |
Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
|
|
CN105555757A
(zh)
*
|
2013-07-23 |
2016-05-04 |
普洛体维生物治疗公司 |
用于递送信使rna的组合物和方法
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
US10202601B2
(en)
|
2013-11-22 |
2019-02-12 |
Mina Therapeutics Limited |
C/EBPα short activating RNA compositions and methods of use
|
|
KR20160089530A
(ko)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용
|
|
IL289736B2
(en)
|
2013-12-12 |
2025-09-01 |
Massachusetts Inst Technology |
Administration, use and therapeutic applications of CRISPR–Cas gene editing systems and gene editing preparations
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
WO2015089351A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
JP2017501149A
(ja)
|
2013-12-12 |
2017-01-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
JP6779866B2
(ja)
|
2014-06-13 |
2020-11-04 |
チルドレンズ メディカル センター コーポレイション |
ミトコンドリアを単離するための製品および方法
|
|
IL298516B2
(en)
|
2014-06-25 |
2025-03-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
EP3160448B1
(en)
*
|
2014-06-26 |
2025-08-06 |
Ramot at Tel-Aviv University Ltd. |
Liposomal formulations for delivery of nucleic acids
|
|
WO2016011226A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
WO2016028682A1
(en)
|
2014-08-17 |
2016-02-25 |
The Broad Institute Inc. |
Genome editing using cas9 nickases
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
RU2017114964A
(ru)
|
2014-10-02 |
2018-11-07 |
Протива Байотерапьютикс, Инк. |
Композиции и способы для подавления экспрессии гена вируса гепатита в
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3234192B1
(en)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
EP3702456A1
(en)
|
2014-12-24 |
2020-09-02 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
TWI813532B
(zh)
|
2015-06-18 |
2023-09-01 |
美商博得學院股份有限公司 |
降低脱靶效應的ｃｒｉｓｐｒ酶突變
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
EP3666895A1
(en)
|
2015-06-18 |
2020-06-17 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
SI3313829T1
(sl)
|
2015-06-29 |
2024-09-30 |
Acuitas Therapeutics Inc. |
Lipidi in formulacije lipidnih nanodelcev za dostavo nukleinskih kislin
|
|
US20180208932A1
(en)
*
|
2015-07-29 |
2018-07-26 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
EP3337908A4
(en)
|
2015-08-18 |
2019-01-23 |
The Broad Institute, Inc. |
METHOD AND COMPOSITIONS FOR CHANGING THE FUNCTION AND STRUCTURE OF CHROMATIN GRINDING AND / OR DOMAINS
|
|
CA2998810A1
(en)
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
US12234454B2
(en)
|
2015-10-22 |
2025-02-25 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4349405A3
(en)
|
2015-10-22 |
2024-06-19 |
ModernaTX, Inc. |
Respiratory virus vaccines
|
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
EP3397261B1
(en)
|
2015-11-30 |
2025-07-09 |
Sana Biotechnology, Inc. |
Sub-mitochondrial particles for use in treating cardiovascular diseases
|
|
ES2924407T3
(es)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Composiciones y procedimientos para el suministro de agentes terapéuticos
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
SMT202200252T1
(it)
|
2015-12-22 |
2022-07-21 |
Modernatx Inc |
Composti e composizioni per il rilascio intracellulare di agenti
|
|
PL3394093T3
(pl)
|
2015-12-23 |
2022-05-16 |
Modernatx, Inc. |
Metody stosowania polinukleotydów kodujących ligand ox40
|
|
EP3400023A1
(en)
|
2016-01-10 |
2018-11-14 |
ModernaTX, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
WO2017124037A1
(en)
|
2016-01-15 |
2017-07-20 |
The Children's Medical Center Corporation |
Therapeutic use of mitochondria and combined mitochondrial agents
|
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
KR102424476B1
(ko)
|
2016-04-19 |
2022-07-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
CA3026110A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
KR20230156150A
(ko)
|
2016-06-17 |
2023-11-13 |
더 브로드 인스티튜트, 인코퍼레이티드 |
제vi형 crispr 오솔로그 및 시스템
|
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
|
CA3034681A1
(en)
|
2016-06-30 |
2018-01-04 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger rna
|
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
WO2018039131A1
(en)
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3596041B1
(en)
|
2017-03-15 |
2022-11-02 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
US11739308B2
(en)
|
2017-03-15 |
2023-08-29 |
The Broad Institute, Inc. |
Cas13b orthologues CRISPR enzymes and systems
|
|
AU2018234814B2
(en)
|
2017-03-15 |
2022-06-30 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
US11338045B2
(en)
|
2017-03-17 |
2022-05-24 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
KR20240155360A
(ko)
|
2017-04-12 |
2024-10-28 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규 타입 vi crispr 오르소로그 및 시스템
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US12350368B2
(en)
|
2017-04-14 |
2025-07-08 |
The Broad Institute, Inc. |
Delivery of large payloads
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
|
DK3622079T3
(da)
|
2017-05-08 |
2025-11-17 |
Flagship Pioneering Innovations V Inc |
Sammensætninger til at gøre membranfusion lettere og anvendelser deraf
|
|
CA3063723A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
EP3625342B1
(en)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
KR20200038236A
(ko)
|
2017-06-13 |
2020-04-10 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
큐론을 포함하는 조성물 및 그의 용도
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
MA49395A
(fr)
|
2017-06-14 |
2020-04-22 |
Modernatx Inc |
Polynucléotides codant pour le facteur viii de coagulation
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US12065396B2
(en)
|
2017-08-17 |
2024-08-20 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11744801B2
(en)
|
2017-08-31 |
2023-09-05 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
WO2019048631A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
|
|
KR102338449B1
(ko)
|
2017-09-21 |
2021-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
|
|
US20200255828A1
(en)
|
2017-10-04 |
2020-08-13 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
WO2019135816A2
(en)
|
2017-10-23 |
2019-07-11 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
WO2019089803A1
(en)
|
2017-10-31 |
2019-05-09 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
EP3706801A4
(en)
|
2017-11-08 |
2022-04-06 |
L.E.A.F Holdings Group LLC |
PLATINUM COMPLEXES AND USES THEREOF
|
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
|
US20230193242A1
(en)
|
2017-12-22 |
2023-06-22 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
JP7490239B2
(ja)
|
2018-02-07 |
2024-05-27 |
エル．イー．エー．エフ． ホールディングス グループ エルエルシー |
ガンマポリグルタミン酸化ペメトレキセドおよびその使用
|
|
WO2019157138A1
(en)
|
2018-02-07 |
2019-08-15 |
L.E.A.F. Holdings Group Llc |
Alpha polyglutamated pemetrexed and uses thereof
|
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
|
CN112236134B
(zh)
|
2018-05-03 |
2024-09-13 |
L.E.A.F.控股集团公司 |
类胡萝卜素组合物及其用途
|
|
US12491265B2
(en)
|
2018-06-18 |
2025-12-09 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
WO2020033601A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
JP7640452B2
(ja)
|
2018-09-19 |
2025-03-05 |
モデルナティエックス インコーポレイテッド |
高純度ｐｅｇ脂質及びそれらの使用
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B1
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
CA3110914A1
(en)
|
2018-09-28 |
2020-04-02 |
Nutcracker Therapeutics, Inc. |
Tertiary amino lipidated cationic peptides for nucleic acid delivery
|
|
CN113166783B
(zh)
|
2018-10-09 |
2024-10-11 |
不列颠哥伦比亚大学 |
包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
|
|
KR20210105889A
(ko)
|
2018-11-09 |
2021-08-27 |
아뷰터스 바이오파마 코포레이션 |
지질 나노입자 제제
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
US20220040281A1
(en)
|
2018-12-21 |
2022-02-10 |
Curevac Ag |
Rna for malaria vaccines
|
|
AU2020205717B2
(en)
|
2019-01-11 |
2025-09-11 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
WO2020247882A1
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Engineered casx systems
|
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
JP7662609B2
(ja)
|
2019-07-18 |
2025-04-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
造血の完全なアブレーションを誘導するための方法
|
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
CA3149914A1
(en)
|
2019-08-06 |
2021-02-11 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
JOP20220037A1
(ar)
|
2019-08-14 |
2023-01-30 |
Acuitas Therapeutics Inc |
جسيمات نانوية دهنية محسنة لتوصيل الأحماض النووية
|
|
CN110564729A
(zh)
*
|
2019-09-17 |
2019-12-13 |
四川大学 |
一种对PLK1基因具有沉默活性且具有高血清稳定性的siRNA及其应用
|
|
US11066355B2
(en)
|
2019-09-19 |
2021-07-20 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
JP2022548399A
(ja)
|
2019-09-23 |
2022-11-18 |
オメガ セラピューティクス， インコーポレイテッド |
肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
EP3886897A1
(en)
|
2020-02-04 |
2021-10-06 |
CureVac AG |
Coronavirus vaccine
|
|
CN115485385A
(zh)
|
2020-03-04 |
2022-12-16 |
瑞泽恩制药公司 |
用于使肿瘤细胞对免疫疗法敏感的方法和组合物
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
AU2021275223A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc. |
Coronavirus antigen compositions and their uses
|
|
CA3179444A1
(en)
|
2020-05-20 |
2021-11-25 |
Avak Kahvejian |
Immunogenic compositions and uses thereof
|
|
MX2022015042A
(es)
|
2020-05-29 |
2023-03-09 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de trem y métodos relacionados con las mismas.
|
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
JP2023530229A
(ja)
|
2020-05-29 |
2023-07-14 |
キュアバック エスイー |
核酸ベースの混合ワクチン
|
|
KR20230035043A
(ko)
|
2020-06-15 |
2023-03-10 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
근이영양증을 위한 아데노-연관 바이러스 벡터 전달
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
CA3189338A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
WO2022023284A1
(en)
|
2020-07-27 |
2022-02-03 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
MA71659A
(fr)
|
2020-08-06 |
2025-05-30 |
Modernatx, Inc. |
Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
TW202218669A
(zh)
|
2020-09-03 |
2022-05-16 |
美商旗艦先鋒創新有限責任公司 |
免疫原性組成物及其用途
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
AU2021360494A1
(en)
|
2020-10-14 |
2023-05-18 |
George Mason Research Foundation, Inc. |
Ionizable lipids and methods of manufacture and use thereof
|
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
|
AU2021385572A1
(en)
|
2020-11-25 |
2023-06-22 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
EP4256054A1
(en)
|
2020-12-03 |
2023-10-11 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
PH12023500013A1
(en)
*
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
JP2024511092A
(ja)
|
2021-03-26 |
2024-03-12 |
ミナ セラピューティクス リミテッド |
ＴＭＥＭ１７３ｓａＲＮＡ組成物及び使用方法
|
|
WO2022200575A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
KR20230165276A
(ko)
|
2021-03-31 |
2023-12-05 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
|
|
US20250345524A1
(en)
|
2021-03-31 |
2025-11-13 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
CA3214538A1
(en)
|
2021-04-20 |
2022-10-27 |
Joel DE BEER |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
WO2022232289A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
AU2022290278A1
(en)
|
2021-06-11 |
2024-01-04 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
US20240350621A1
(en)
|
2021-08-06 |
2024-10-24 |
University Of Iowa Research Foundation |
Double stranded mrna vaccines
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
CA3230031A1
(en)
|
2021-09-03 |
2023-03-09 |
Patrick Baumhof |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
EP4402121A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
TW202330916A
(zh)
|
2021-09-17 |
2023-08-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸之組成物和方法
|
|
IL311610A
(en)
|
2021-09-21 |
2024-05-01 |
Scribe Therapeutics Inc |
Engineered casx repressor systems
|
|
TW202322826A
(zh)
|
2021-10-18 |
2023-06-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物及方法
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
EP4430024A1
(en)
|
2021-11-08 |
2024-09-18 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2023086465A1
(en)
|
2021-11-12 |
2023-05-19 |
Modernatx, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
CA3238292A1
(en)
|
2021-11-16 |
2023-05-25 |
Alessandra Bartolozzi |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
KR20240128683A
(ko)
|
2021-11-22 |
2024-08-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
CN118401544A
(zh)
|
2021-11-24 |
2024-07-26 |
旗舰创业创新六公司 |
水痘-带状疱疹病毒免疫原组合物及其用途
|
|
EP4436598A2
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and their uses
|
|
EP4436984A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US20240401024A1
(en)
|
2021-12-17 |
2024-12-05 |
Flagship Pioneering Innovations Vi, Llc |
Methods for enrichment of circular rna under denaturing conditions
|
|
CA3241061A1
(en)
|
2021-12-22 |
2023-06-29 |
Alexandra Sophie DE BOER |
Compositions and methods for purifying polyribonucleotides
|
|
CA3243054A1
(en)
|
2021-12-23 |
2025-04-08 |
Renagade Therapeutics Management Inc. |
Constrained Lipids and Associated Utilization Processes
|
|
EP4452337A1
(en)
|
2021-12-23 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
EP4463475A2
(en)
|
2022-01-14 |
2024-11-20 |
Anjarium Biosciences AG |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
US20250084389A1
(en)
|
2022-01-17 |
2025-03-13 |
Institut National de la Santé et de la Recherche Médicale |
Methods of inducing cell death of a population of solid tumor cells
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
AU2023212857A1
(en)
|
2022-01-27 |
2024-07-04 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
WO2023154818A1
(en)
|
2022-02-09 |
2023-08-17 |
Modernatx, Inc. |
Mucosal administration methods and formulations
|
|
JP2025505711A
(ja)
|
2022-02-14 |
2025-02-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
リンパ浮腫の処置のための１５－リポキシゲナーゼの使用
|
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
AU2023238223A1
(en)
|
2022-03-23 |
2024-10-10 |
Nanovation Therapeutics Inc. |
High sterol-containing lipid nanoparticles
|
|
JP2025510229A
(ja)
|
2022-03-25 |
2025-04-14 |
セイル バイオメディシンズ インコーポレイテッド |
新規のイオン化脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
CN119654166A
(zh)
|
2022-04-01 |
2025-03-18 |
内诺维什疗法股份有限公司 |
mRNA递送方法及其组合物
|
|
AU2023250649A1
(en)
|
2022-04-04 |
2024-11-14 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
CN118900914A
(zh)
|
2022-04-27 |
2024-11-05 |
上海瑞宏迪医药有限公司 |
核酸构建体及其应用
|
|
CA3257006A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
雙股ｄｎａ組合物及相關方法
|
|
JP2025515206A
(ja)
|
2022-05-13 |
2025-05-13 |
上海瑞宏迪医薬有限公司 |
Ｕｔｒを含む核酸構築物及びその使用
|
|
CN119562966A
(zh)
|
2022-05-13 |
2025-03-04 |
生物技术公司 |
靶向hiv的rna组合物
|
|
JP2025522297A
(ja)
|
2022-05-25 |
2025-07-15 |
ビオンテック エスエー |
サルポックス抗原の送達のためのｒｎａ組成物及び関連する方法
|
|
EP4531902A1
(en)
|
2022-05-25 |
2025-04-09 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
AU2023275780A1
(en)
|
2022-05-25 |
2024-12-05 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
US20250375534A1
(en)
|
2022-05-30 |
2025-12-11 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
|
TW202411426A
(zh)
|
2022-06-02 |
2024-03-16 |
美商斯奎柏治療公司 |
經工程化的２類ｖ型ｃｒｉｓｐｒ系統
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Compositions of lipid nanoparticles and their uses
|
|
IL317529A
(en)
|
2022-06-07 |
2025-02-01 |
Scribe Therapeutics Inc |
Compositions and methods for targeting PCSK9
|
|
EP4536819A1
(en)
|
2022-06-07 |
2025-04-16 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
CN119947741A
(zh)
|
2022-07-25 |
2025-05-06 |
法国国家健康与医学研究院 |
使用艾帕素治疗淋巴水肿
|
|
KR20250044720A
(ko)
|
2022-08-01 |
2025-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
면역조절 단백질 및 관련 방법
|
|
AU2023323547A1
(en)
|
2022-08-12 |
2025-03-20 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
CN120239693A
(zh)
|
2022-08-31 |
2025-07-01 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及其使用方法
|
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
WO2024064934A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
CN120283052A
(zh)
|
2022-09-23 |
2025-07-08 |
恩科洛玛生物公司 |
用于表观遗传调控hbv基因表达的组合物和方法
|
|
IL319414A
(en)
|
2022-09-23 |
2025-05-01 |
BioNTech SE |
Compositions for delivering antigens at the liver level and related methods
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
EP4598954A1
(en)
|
2022-10-06 |
2025-08-13 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
|
AU2023372397A1
(en)
|
2022-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
JP2025537178A
(ja)
|
2022-11-08 |
2025-11-14 |
オーナ セラピューティクス， インコーポレイテッド |
環状ｒｎａ組成物
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
AR131008A1
(es)
|
2022-11-08 |
2025-02-05 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
IL320870A
(en)
|
2022-12-01 |
2025-07-01 |
Generation Bio Co |
Lipid nanoparticles containing nucleic acids, ionizable lipids, sterols, lipid-anchored polymers and auxiliary lipids and their uses
|
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
EP4626400A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
AU2023391361A1
(en)
|
2022-12-08 |
2025-06-05 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
EP4630033A1
(en)
|
2022-12-09 |
2025-10-15 |
Institut National de la Santé et de la Recherche Médicale |
Novel human antiviral genes related to the eleos and lamassu prokaryotic systems
|
|
EP4634388A1
(en)
|
2022-12-14 |
2025-10-22 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024151685A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024149697A1
(en)
|
2023-01-09 |
2024-07-18 |
Institut National de la Santé et de la Recherche Médicale |
Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating adverse post-ischemic cardiac remodeling in a patient who experienced a myocardial infarction
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024153636A1
(en)
|
2023-01-17 |
2024-07-25 |
Institut National de la Santé et de la Recherche Médicale |
Vasorin as a biomarker and biotarget in nephrology
|
|
WO2024156835A1
(en)
|
2023-01-27 |
2024-08-02 |
Institut National de la Santé et de la Recherche Médicale |
Use of amphiregulin (areg) in methods of treating vascular hyperpermeability
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024173828A1
(en)
|
2023-02-17 |
2024-08-22 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
|
WO2024173836A2
(en)
|
2023-02-17 |
2024-08-22 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
DE112024001143T5
(de)
|
2023-03-08 |
2025-12-18 |
CureVac SE |
Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
|
|
AU2024235803A1
(en)
|
2023-03-15 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
WO2024194484A1
(en)
|
2023-03-23 |
2024-09-26 |
Institut National de la Santé et de la Recherche Médicale |
Modulating the expression and/or activity of gas7 for modulating viral replication
|
|
TW202444906A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向pcsk9之組合物及方法
|
|
TW202444910A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
編碼casx之信使rna
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202444921A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向lpa之組合物及方法
|
|
WO2024206565A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
AU2024252590A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
CN121001738A
(zh)
|
2023-04-27 |
2025-11-21 |
葛兰素史克生物有限公司 |
流感病毒疫苗
|
|
CN121038807A
(zh)
|
2023-05-03 |
2025-11-28 |
生物技术欧洲股份公司 |
优化的csp变体及相关方法
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025021083A1
(en)
*
|
2023-07-24 |
2025-01-30 |
National Institute Of Biological Sciences, Beijing |
Lipid nanoparticle compositions for localized treatment of skin diseases
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024486A2
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025046121A1
(en)
|
2023-09-01 |
2025-03-06 |
Novoarc Gmbh |
Lipid nanoparticle with nucleic acid cargo and ionizable lipid
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072293A1
(en)
|
2023-09-27 |
2025-04-03 |
Scribe Therapeutics Inc. |
Optimized mrnas encoding casx proteins
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025083211A1
(en)
|
2023-10-20 |
2025-04-24 |
Institut National de la Santé et de la Recherche Médicale |
Use of factor h for the treatment of dementia
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
US20250162981A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025215072A1
(en)
|
2024-04-10 |
2025-10-16 |
Institut National de la Santé et de la Recherche Médicale |
Class i lanthipeptides with anti-viral function
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025248096A1
(en)
|
2024-05-31 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Antimicrobial peptides having liquid-liquid phase separation activities
|
|
WO2025259931A1
(en)
|
2024-06-14 |
2025-12-18 |
Orbital Therapeutics, Inc. |
Compositions and methods for rna circularization
|